Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kala BioFRA:27F 18 Market Cap is €12.66 Mil as of Jul. 18, 2026. GuruFocus rates FRA:27F with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Kala Bio ranks worse than 79.41% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Kala Bio's share price for the quarter that ended in Mar. 2026 was €0.1409. Kala Bio's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 18.59 Mil. Therefore, Kala Bio's market cap for the quarter that ended in Mar. 2026 was €2.62 Mil.
Kala Bio's quarterly market cap
increased
from Sep. 2025 (€0.23 Mil) to Dec. 2025 (€0.28 Mil) and
increased
from Dec. 2025 (€0.28 Mil) to Mar. 2026 (€2.62 Mil).
Kala Bio's annual market cap
increased
from Dec. 2023 (€0.36 Mil) to Dec. 2024 (€0.80 Mil) but then
declined
from Dec. 2024 (€0.80 Mil) to Dec. 2025 (€0.28 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kala Bio's Enterprise Value for Today is €6.03 Mil.
Kala Bio (FRA:27F) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Kala Bio Market Cap Related Terms
Kala Bio Market Cap Historical Data
* Premium members only.
The historical data trend for Kala Bio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kala Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kala Bio Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kala Bio's Market Cap distribution charts can be found below:
* The bar in red indicates where Kala Bio's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Kala Bio's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kala Bio (FRA:27F) has a Market Cap of €12.66 Mil as of Jul. 18, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kala Bio and its competitors. According to the industry distribution chart, Kala Bio ranks #1130 out of 1423 companies in the Biotechnology industry, placing it in the top 79.4%.
Is Kala Bio's Market Cap too high?
Kala Bio's current Market Cap is €12.66 Mil. Based on the distribution chart, Kala Bio ranks #1130 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kala Bio has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Kala Bio's Market Cap compare to MGX and HYPD?
According to the Biotechnology industry distribution chart, Kala Bio ranks #1130 out of 1423 companies for Market Cap. This places Kala Bio in the lower half of its industry. The industry median Market Cap is 113.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.78, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kala Bio and its competitors. For the Biotechnology industry, the median Market Cap is 113.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kala Bio's current Market Cap is €12.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kala Bio stock overvalued right now?
Kala Bio (FRA:27F) has a current Market Cap of €12.66 Mil. The current Market Cap is €12.66 Mil. Kala Bio's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Kala Bio (FRA:27F), the current Market Cap is €12.66 Mil as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
18GF Score
Get the complete analysis for FRA:27F
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:27F has been successfully added to your 
